NCT00353756View on ClinicalTrials.gov

Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease

PHASE1UnknownINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 30, 2006

Study Completion Date

September 30, 2007

Conditions
Crohn's Disease
Interventions
DRUG

C326, IL-6 Inhibitory Avimer protein

Trial Locations (2)

Unknown

RECRUITING

QPharm, Brisbane

RECRUITING

Center for Clinical Studies, Melbourne

Sponsors

Lead Sponsor

Avidia
All Listed Sponsors
lead

Avidia

INDUSTRY

NCT00353756 - Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease | Biotech Hunter | Biotech Hunter